• 1. Vapour-phase chemical derivatisation for the determination of surface functional groups by X-ray photoelectron spectroscopy
  Rohit P. Popat,Ian Sutherland,En-Shang Sheng J. Mater. Chem. 1995 5 713
• 2. Vapour-phase chemical derivatisation for the determination of surface functional groups by X-ray photoelectron spectroscopy
  Rohit P. Popat,Ian Sutherland,En-Shang Sheng J. Mater. Chem. 1995 5 713

• Other Chemical Reagents

Introduction to [3-(trifluoromethyl)phenyl]hydrazine (CAS No. 368-78-5)

[3-(trifluoromethyl)phenyl]hydrazine is a significant compound in the field of pharmaceutical chemistry, characterized by its unique structural and chemical properties. This compound, with the CAS number 368-78-5, has garnered considerable attention due to its potential applications in the development of novel therapeutic agents. The presence of a [trifluoromethyl] group in its molecular structure imparts distinct reactivity and stability, making it a valuable intermediate in synthetic chemistry.

The [trifluoromethyl]phenyl moiety is particularly noteworthy, as trifluoromethyl groups are known for their ability to enhance metabolic stability and binding affinity in drug molecules. This feature has led to extensive research into derivatives of [3-(trifluoromethyl)phenyl]hydrazine, exploring its utility in medicinal chemistry. Recent studies have highlighted its role in the synthesis of bioactive molecules, particularly those targeting neurological and inflammatory disorders.

In the realm of drug discovery, [3-(trifluoromethyl)phenyl]hydrazine has been employed as a key building block in the construction of heterocyclic compounds. These heterocycles often exhibit enhanced pharmacological properties, including improved solubility and bioavailability. The hydrazine group itself is a versatile functional unit, capable of participating in various chemical transformations such as condensation reactions with carbonyl compounds, leading to the formation of hydrazones and other pharmacologically relevant structures.

Recent advancements in computational chemistry have further elucidated the potential of [3-(trifluoromethyl)phenyl]hydrazine in drug design. Molecular modeling studies have demonstrated its favorable interactions with biological targets, suggesting its suitability for developing small-molecule inhibitors. These studies have been complemented by experimental investigations, which have validated the compound's efficacy in preclinical models.

The synthesis of [3-(trifluoromethyl)phenyl]hydrazine involves multi-step organic reactions, typically starting from commercially available aromatic precursors. The introduction of the trifluoromethyl group is often achieved through halogenation followed by metal-catalyzed cross-coupling reactions. These synthetic strategies have been optimized to ensure high yields and purity, crucial for pharmaceutical applications.

One of the most promising areas of research involving [3-(trifluoromethyl)phenyl]hydrazine is its application in the development of anti-inflammatory agents. The compound's ability to modulate inflammatory pathways has been demonstrated in vitro and in vivo studies. Specifically, derivatives of this compound have shown inhibitory effects on enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are central to inflammatory processes.

Another significant application lies in the field of neurology. Preliminary research indicates that [3-(trifluoromethyl)phenyl]hydrazine derivatives may exhibit neuroprotective properties, making them potential candidates for treating neurodegenerative diseases such as Alzheimer's and Parkinson's. The compound's ability to cross the blood-brain barrier has been a key focus, ensuring its efficacy in central nervous system disorders.

The role of [3-(trifluoromethyl)phenyl]hydrazine in anticancer research is also noteworthy. Studies have shown that certain derivatives can induce apoptosis in cancer cells by inhibiting key signaling pathways involved in tumor growth and survival. The trifluoromethyl group enhances the compound's ability to interact with biological targets, thereby improving its therapeutic potential.

In conclusion, [3-(trifluoromethyl)phenyl]hydrazine (CAS No. 368-78-5) is a multifaceted compound with significant implications in pharmaceutical chemistry. Its unique structural features make it a valuable tool for developing novel therapeutic agents across various disease areas. Ongoing research continues to uncover new applications and refine synthetic methodologies, ensuring its continued relevance in drug discovery efforts.

• 368-90-1(4-(Trifluoromethyl)phenylhydrazine)
• 886-35-1(3,5-Bis(trifluoromethyl)phenylhydrazine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)